SAB Biotherapeutics Inc (SABS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.720.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SABS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -58.0% |
| Our one-year growth estimate | diamond | -95.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 37.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SABS — litigation filed
Dated 2026-07-07
Regulation FD Disclosure. On July 7, 2026, SAB Biotherapeutics, Inc., a Delaware corporation (the “Company” or “SAB BIO”) issued a press release with Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, announcing that Breakthrough T1D, has awarded a grant to Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida in support of PRISE-hATG, a clinical study evaluating SAB-142 in patients with Stage 3 T1D who…
Why it matters: This partnership is crucial for SAB-142's production. Progress can signal operational strength.
Watch forLook for news about a signed deal or progress in manufacturing with Emergent.
Also watch forNo news or problems in the partnership with Emergent BioSolutions.
Why it matters: Results will indicate if SAB-142 can help patients with Stage 3 T1D beyond 100 days from diagnosis. This could expand treatment options.
Supportive ifThe PRISE-hATG study shows better beta cell function in patients.
Worry ifThe PRISE-hATG study shows no better beta cell function.
Why it matters: Updates will show if SAB BIO can secure production for SAB-142, crucial for future sales.
Supportive ifWatch for news about successful production runs for SAB-142.
Worry ifDelays or problems reported in making SAB-142.
Why it matters: Revenue growth is important for the company's weak financial status. A rebound could show recovery.
Supportive ifRevenue growth speeds up toward previous highs. This shows stronger demand.
Worry ifRevenue growth slows down or stays below 10 percent. This shows ongoing weakness.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$198 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $657 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,011 loss on $10,000 · 30.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Topline data will show how well SAB-142 works in treating Stage 3 T1D. This data is crucial for the company's future.
Supportive ifThe SAFEGUARD trial shows good results for SAB-142.
Worry ifThe data shows no good results for SAB-142.
Why it matters: Results will indicate if SAB-142 can preserve beta cell function beyond 100 days after diagnosis. This could expand treatment options.
Supportive ifThe PRISE-hATG study shows good results in keeping C-peptide levels after 100 days.
Worry ifThe study shows no big change in C-peptide levels after 100 days.
Why it matters: Changes in cash flow will indicate if SAB BIO is managing its finances better. This is crucial for long-term viability.
Worry ifOperating losses drop from -$23.4M in 2026-Q2 to under -$20M.
Less concerning ifOperating losses increase or remain above -$23.4M in the next quarter.
Why it matters: Topline data will show if SAB-142 is effective in treating Stage 3 T1D. This is crucial for the company's growth.
Supportive ifThe SAFEGUARD trial shows big gains in C-peptide levels for treated patients.
Worry ifThe data shows no big change in C-peptide levels compared to placebo.